Market research
ADVIC.PA Advicenne S.A
PA EUR Healthcare
Latest close
As of 29 Dec 2024
Test a moving-average rule with historical data.
Market facts
- Market cap
- 65M
- P/E ratio
- Not available
- Analyst target
- 20.95
- Dividend yield
- 0.0%
- Beta
- 1.43
Profile
Instrument facts
- Exchange
- PA
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- ISIN
- FR0013296746
- Market cap
- 65M
- P/E ratio
- Not available
- Analyst target
- 20.95
- Dividend yield
- 0.0%
- Beta
- 1.43
About
About Advicenne S.A
Advicenne S.A. develops therapeutics for the treatment of rare kidney diseases. Its lead product candidate is ADV7103 for the treatment of distal renal tubular acidosis in children and adults, as well as for the treatment of cystinuria, an inherited renal tubulopathy. The company also provides ADV6209, an oral liquid solution for children to reduce anxiety and to improve their immobility. Advicenne S.A. was founded in 2007 and is based in Paris, France.
Research context
Advicenne S.A appears in PyInvesting’s Paris Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Pharmaceuticals
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ADVIC.PA discussion.
5 years, 6 months ago
Advicenne S.A is currently in a long term downtrend where the price is trading 31.4% below its 200 day moving average.
From a valuation standpoint, the stock is 84.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 43.8.
Based on the above factors, Advicenne S.A gets an overall score of 1/5.